| Issue |
Med Sci (Paris)
Volume 33, Number 4, Avril 2017
|
|
|---|---|---|
| Page(s) | 441 - 444 | |
| Section | Forum | |
| DOI | https://doi.org/10.1051/medsci/20173304015 | |
| Published online | 12 May 2017 | |
Les chimères du dépistage
Chroniques Génomiques
Cancer screening fantasies
UMR 7268 ADÉS, Aix-Marseille, Université/EFS/CNRS, Espace éthique méditerranéen, hôpital d’adultes la Timone, 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France ;
CoReBio PACA, case 901, parc scientifique de Luminy, 13288 Marseille Cedex 09, France
*
bertrand.jordan@univ-amu.fr ; brjordan@orange.fr
Abstract
The use of circulating tumour DNA to screen for cancer in asymptomatic individuals is the goal of Grail, initially set up by Illumina. This company is now raising a large amount of capital to develop this project on a much longer time scale than initially announced. Although it has access to cutting edge technology and is led by excellent scientists, the prospect for success in this application is rather bleak, mainly because of the extreme requirements for specificity in order to avoid overdiagnosis.
© 2017 médecine/sciences – Inserm
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.